Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | KRAS | P01116 | 7/20 | 0.59 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275000 | 0.96 | HINT1 (0.66) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| SCHEMBL18520136 | 0.89 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL1138984 | 0.87 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| SCHEMBL2014087 | 0.87 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7111080 | 0.87 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 0.87 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.87 | HINT1 (0.75) | HINT1NT5EADORA3GSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024565-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180237467-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9968628-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-30 | — | — | US | disclosed |
| CN-104163841-B | For treating 2 ' and 3 '-nucleoside prodrugs of the modification of flaviviridae infections | 埃迪尼克斯医药公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9216960-B2 | Spiro[2.4]heptanes for treatment of Flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| CN-1443191-A | Methods and compositions for treating hepatitis c virus | IDENNIKOS KY CO LTD (KY) | 2003-09-17 | — | — | CN | disclosed |
| WO-2003026675-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES USING 4'-MODIFIED NUCLEOSIDE | IDENIX (CAYMAN) LIMITED (KY) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026589-A2 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS USING 4'-MODIFIED NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2003-04-03 | — | — | WO | disclosed |
| US-20030060400-A1 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC | 2003-03-27 | — | — | US | disclosed |
| EP-1294735-A2 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | Novirio Pharmaceuticals Limited (KY) | 2003-03-26 | — | — | EP | disclosed |
| EP-1292603-A2 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | Novirio Pharmaceuticals Limited (KY) | 2003-03-19 | — | — | EP | disclosed |
| US-20030050229-A1 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC | 2003-03-13 | — | — | US | disclosed |
| WO-2001092282-A2 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001090121-A2 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX (CAYMAN) LIMITED (KY) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | MTAP, PHOSPHO1, PNP | HINT1 421/4885NT5E 324/4885ADORA3 1821/4885 |
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | HINT1 587/4885NT5E 407/4885ADORA3 482/4885 |
| US-20030060400-A1 | Methods and compositions for treating flaviviruses and pestiviruses | PHOSPHO1, MTAP, PNP | HINT1 528/4885NT5E 577/4885ADORA3 1595/4885 |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | HINT1 587/4885NT5E 407/4885ADORA3 482/4885 |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | HINT1 587/4885NT5E 407/4885ADORA3 482/4885 |
| US-20180237467-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | HINT1 315/4885NT5E 50/4885ADORA3 178/4885 |
| US-20030050229-A1 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, SLC10A1 | HINT1 417/4885NT5E 392/4885ADORA3 330/4885 |
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | HINT1 315/4885NT5E 50/4885ADORA3 178/4885 |
| US-20210024565-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | HINT1 363/4885NT5E 65/4885ADORA3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.